INmune Historical Balance Sheet

INMB Stock

USD 7.67 1.14 17.46%

Trend analysis of INmune Bio balance sheet accounts such as Total Current Liabilities of 22.3 M or Total Stockholder Equity of 33.6 M provides information on INmune Bio's total assets, liabilities, and equity, which is the actual value of INmune Bio to its prevalent stockholders. By breaking down trends over time using INmune Bio balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining INmune Bio latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether INmune Bio is a good buy for the upcoming year.

INmune Bio Inventory

41,055

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in INmune Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.

About INmune Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of INmune Bio at a specified time, usually calculated after every quarter, six months, or one year. INmune Bio Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of INmune Bio and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which INmune currently owns. An asset can also be divided into two categories, current and non-current.

INmune Bio Balance Sheet Chart

At present, INmune Bio's Total Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 52.6 M, whereas Total Assets are forecasted to decline to about 41.6 M.

Total Assets Other Current Liab Total Current Liabilities Accounts Payable

Add Fundamental

Total Assets

Total assets refers to the total amount of INmune Bio assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in INmune Bio books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on INmune Bio balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of INmune Bio are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Accounts Payable

An accounting item on the balance sheet that represents INmune Bio obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of INmune Bio are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most accounts from INmune Bio's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into INmune Bio current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in INmune Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.At present, INmune Bio's Total Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 52.6 M, whereas Total Assets are forecasted to decline to about 41.6 M.

	2022	2023	2024	2025 (projected)
Other Current Liabilities	538K	524K	471.6K	448.0K
Total Assets	81.8M	57.0M	65.6M	41.6M

Other Current Liab Total Assets

INmune Bio balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Capital Surpluse	Total Liab	Total Current Assets	Common Stock	Short Long Term Debt Total	Net Debt	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Short Long Term Debt	Short Term Debt	Net Invested Capital	Net Working Capital	Intangible Assets	Retained Earnings Total Equity
Total Assets		-0.12	0.62	0.99	0.93	-0.82	0.72	0.98	0.98	0.89	0.87	0.98	0.41	0.93	-0.96	0.89	0.95	0.83	-0.02	0.88	0.68	0.5	0.97	0.93	-0.24	-0.86
Other Current Liab	-0.12		-0.27	-0.05	-0.31	0.25	-0.26	-0.28	-0.28	-0.21	-0.31	-0.28	-0.23	-0.32	0.27	-0.25	-0.09	-0.35	0.54	-0.2	0.11	-0.29	-0.3	-0.28	0.17	0.31
Total Current Liabilities	0.62	-0.27		0.55	0.81	-0.94	0.99	0.58	0.58	0.9	0.89	0.59	0.95	0.72	-0.54	0.51	0.76	0.86	-0.14	0.91	0.89	0.99	0.58	0.46	-0.75	-0.9
Total Stockholder Equity	0.99	-0.05	0.55		0.9	-0.76	0.66	0.96	0.96	0.85	0.81	0.96	0.33	0.87	-0.96	0.87	0.92	0.75	0.02	0.84	0.66	0.42	0.95	0.94	-0.22	-0.8
Net Tangible Assets	0.93	-0.31	0.81	0.9		-0.92	0.88	0.93	0.93	0.97	0.96	0.93	0.65	0.92	-0.93	0.8	0.91	0.87	-0.11	0.96	0.78	0.71	0.94	0.88	-0.52	-0.93
Retained Earnings	-0.82	0.25	-0.94	-0.76	-0.92		-0.97	-0.78	-0.78	-0.97	-0.95	-0.79	-0.82	-0.86	0.75	-0.71	-0.91	-0.92	0.07	-0.98	-0.88	-0.89	-0.77	-0.67	0.56	0.98
Accounts Payable	0.72	-0.26	0.99	0.66	0.88	-0.97		0.69	0.69	0.95	0.94	0.69	0.91	0.79	-0.65	0.6	0.83	0.89	-0.13	0.96	0.91	0.96	0.68	0.57	-0.73	-0.94
Cash	0.98	-0.28	0.58	0.96	0.93	-0.78	0.69		1.0	0.85	0.86	1.0	0.37	0.95	-0.98	0.89	0.9	0.83	-0.1	0.84	0.58	0.47	0.99	0.97	-0.21	-0.84
Cash And Short Term Investments	0.98	-0.28	0.58	0.96	0.93	-0.78	0.69	1.0		0.85	0.86	1.0	0.37	0.95	-0.98	0.89	0.9	0.83	-0.1	0.84	0.58	0.47	0.99	0.97	-0.21	-0.84
Capital Surpluse	0.89	-0.21	0.9	0.85	0.97	-0.97	0.95	0.85	0.85		0.97	0.86	0.75	0.89	-0.84	0.77	0.93	0.89	-0.05	1.0	0.89	0.82	0.85	0.77	-0.6	-0.97
Total Liab	0.87	-0.31	0.89	0.81	0.96	-0.95	0.94	0.86	0.86	0.97		0.87	0.73	0.95	-0.83	0.81	0.88	0.93	-0.16	0.97	0.8	0.83	0.87	0.8	-0.58	-0.97
Total Current Assets	0.98	-0.28	0.59	0.96	0.93	-0.79	0.69	1.0	1.0	0.86	0.87		0.36	0.95	-0.98	0.91	0.9	0.83	-0.1	0.84	0.57	0.47	0.99	0.97	-0.21	-0.85
Common Stock	0.41	-0.23	0.95	0.33	0.65	-0.82	0.91	0.37	0.37	0.75	0.73	0.36		0.51	-0.34	0.22	0.59	0.71	-0.12	0.77	0.86	0.96	0.36	0.22	-0.79	-0.73
Short Long Term Debt Total	0.93	-0.32	0.72	0.87	0.92	-0.86	0.79	0.95	0.95	0.89	0.95	0.95	0.51		-0.9	0.9	0.88	0.92	-0.17	0.88	0.62	0.64	0.94	0.89	-0.32	-0.92
Net Debt	-0.96	0.27	-0.54	-0.96	-0.93	0.75	-0.65	-0.98	-0.98	-0.84	-0.83	-0.98	-0.34	-0.9		-0.87	-0.86	-0.74	0.08	-0.82	-0.57	-0.42	-0.99	-0.98	0.23	0.81
Net Receivables	0.89	-0.25	0.51	0.87	0.8	-0.71	0.6	0.89	0.89	0.77	0.81	0.91	0.22	0.9	-0.87		0.78	0.74	-0.11	0.75	0.45	0.41	0.91	0.9	-0.17	-0.81
Common Stock Total Equity	0.95	-0.09	0.76	0.92	0.91	-0.91	0.83	0.9	0.9	0.93	0.88	0.9	0.59	0.88	-0.86	0.78		0.9	0.03	0.93	0.82	0.67	0.86	0.79	-0.33	-0.91
Common Stock Shares Outstanding	0.83	-0.35	0.86	0.75	0.87	-0.92	0.89	0.83	0.83	0.89	0.93	0.83	0.71	0.92	-0.74	0.74	0.9		-0.23	0.89	0.74	0.8	0.8	0.69	-0.41	-0.94
Other Current Assets	-0.02	0.54	-0.14	0.02	-0.11	0.07	-0.13	-0.1	-0.1	-0.05	-0.16	-0.1	-0.12	-0.17	0.08	-0.11	0.03	-0.23		-0.06	0.06	-0.15	-0.11	-0.1	0.09	0.12
Other Stockholder Equity	0.88	-0.2	0.91	0.84	0.96	-0.98	0.96	0.84	0.84	1.0	0.97	0.84	0.77	0.88	-0.82	0.75	0.93	0.89	-0.06		0.9	0.84	0.84	0.76	-0.62	-0.97
Short Long Term Debt	0.68	0.11	0.89	0.66	0.78	-0.88	0.91	0.58	0.58	0.89	0.8	0.57	0.86	0.62	-0.57	0.45	0.82	0.74	0.06	0.9		0.85	0.56	0.46	-0.69	-0.81
Short Term Debt	0.5	-0.29	0.99	0.42	0.71	-0.89	0.96	0.47	0.47	0.82	0.83	0.47	0.96	0.64	-0.42	0.41	0.67	0.8	-0.15	0.84	0.85		0.46	0.33	-0.77	-0.84
Net Invested Capital	0.97	-0.3	0.58	0.95	0.94	-0.77	0.68	0.99	0.99	0.85	0.87	0.99	0.36	0.94	-0.99	0.91	0.86	0.8	-0.11	0.84	0.56	0.46		0.99	-0.26	-0.84
Net Working Capital	0.93	-0.28	0.46	0.94	0.88	-0.67	0.57	0.97	0.97	0.77	0.8	0.97	0.22	0.89	-0.98	0.9	0.79	0.69	-0.1	0.76	0.46	0.33	0.99		-0.2	-0.75
Intangible Assets	-0.24	0.17	-0.75	-0.22	-0.52	0.56	-0.73	-0.21	-0.21	-0.6	-0.58	-0.21	-0.79	-0.32	0.23	-0.17	-0.33	-0.41	0.09	-0.62	-0.69	-0.77	-0.26	-0.2		0.49
Retained Earnings Total Equity	-0.86	0.31	-0.9	-0.8	-0.93	0.98	-0.94	-0.84	-0.84	-0.97	-0.97	-0.85	-0.73	-0.92	0.81	-0.81	-0.91	-0.94	0.12	-0.97	-0.81	-0.84	-0.84	-0.75	0.49

Click cells to compare fundamentals

INmune Bio Account Relationship Matchups

INmune Bio balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	40.7M	99.9M	81.8M	57.0M	65.6M	41.6M
Other Current Liab	224.3K	412K	538K	524K	471.6K	448.0K
Total Current Liabilities	1.8M	4.4M	10.9M	18.5M	21.2M	22.3M
Total Stockholder Equity	38.8M	80.2M	60.1M	38.1M	43.9M	33.6M
Net Tangible Assets	7.1M	22.2M	63.7M	43.6M	50.1M	52.6M
Retained Earnings	(33.4M)	(63.7M)	(91.0M)	(121.0M)	(108.9M)	(103.5M)
Accounts Payable	1.5M	3.8M	5.2M	7.9M	9.1M	9.5M
Cash	22.0M	74.8M	52.2M	35.8M	41.2M	23.6M
Cash And Short Term Investments	22.0M	74.8M	52.2M	35.8M	41.2M	23.6M
Capital Surpluse	44.8M	72.1M	143.9M	151.8M	174.6M	183.3M
Total Liab	1.9M	19.7M	21.7M	18.9M	21.7M	22.8M
Total Current Assets	24.0M	82.6M	64.7M	39.9M	45.9M	27.2M
Common Stock	10.8K	13.5K	18K	817K	939.6K	986.5K
Short Long Term Debt Total	160.2K	15.2M	15.3M	10.4M	12.0M	7.6M
Net Debt	(21.8M)	(59.6M)	(36.8M)	(25.4M)	(22.9M)	(24.0M)
Non Current Assets Total	16.7M	17.3M	17.1M	17.1M	19.6M	16.2M
Net Receivables	1.8M	5.5M	8.5M	2.4M	2.8M	2.8M
Common Stock Total Equity	8.7K	10.8K	13.5K	18K	20.7K	12.9K
Common Stock Shares Outstanding	12.0M	16.1M	17.9M	18.0M	20.7M	14.8M
Liabilities And Stockholders Equity	40.7M	99.9M	81.8M	57.0M	65.6M	46.8M
Non Current Liabilities Total	126.3K	15.4M	10.8M	397K	456.6K	433.7K
Other Current Assets	220K	2.3M	4.1M	1.7M	1.5M	1.4M
Other Stockholder Equity	72.1M	143.9M	151.8M	159.1M	183.0M	192.2M
Accumulated Other Comprehensive Income	10.7K	1K	(699K)	(799K)	(719.1K)	(683.1K)
Short Term Debt	34K	144K	5.2M	10.0M	11.5M	12.1M
Net Invested Capital	38.8M	94.7M	74.8M	48.1M	55.3M	49.4M
Net Working Capital	22.2M	78.2M	53.8M	21.5M	24.7M	29.0M
Retained Earnings Total Equity	(21.3M)	(33.4M)	(63.7M)	(91.0M)	(81.9M)	(77.8M)
Capital Stock	10.8K	13.5K	18K	817K	939.6K	986.5K
Property Plant And Equipment Net	156.2K	726K	507K	414K	476.1K	438.8K
Current Deferred Revenue	190.6K	474K	616K	489K	562.4K	590.5K
Capital Lease Obligations	160.2K	776K	613K	516K	593.4K	491.4K
Property Plant And Equipment Gross	156.2K	726K	507K	414K	476.1K	438.8K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

MSFT	Microsoft
V	Visa Class A
C	Citigroup

When determining whether INmune Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of INmune Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Inmune Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Inmune Bio Stock:

How To Invest In INmune

Details

Is INmune Stock a good investment?

Details

What is INmune Bio's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.

You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of INmune Bio. If investors know INmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about INmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.18)

Revenue Per Share

0.002

Quarterly Revenue Growth

(0.63)

Return On Assets

(0.45)

Return On Equity

(0.99)

The market value of INmune Bio is measured differently than its book value, which is the value of INmune that is recorded on the company's balance sheet. Investors also form their own opinion of INmune Bio's value that differs from its market value or its book value, called intrinsic value, which is INmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because INmune Bio's market value can be influenced by many factors that don't directly affect INmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between INmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if INmune Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, INmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

INmune Historical Balance Sheet

INmune Bio Inventory

41,055

About INmune Balance Sheet Analysis

INmune Bio Balance Sheet Chart

Total Assets

Total Current Liabilities

Accounts Payable

INmune Bio balance sheet Correlations

INmune Bio Account Relationship Matchups

High Positive Relationship

High Negative Relationship

INmune Bio balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments
Other Stockholder Equity	+ 1.0	Capital Surpluse
Total Stockholder Equity	+ 0.99	Total Assets
Accounts Payable	+ 0.99	Total Current Liabilities

Net Invested Capital	- 0.99	Net Debt
Net Working Capital	- 0.98	Net Debt
Net Debt	- 0.98	Total Current Assets
Net Debt	- 0.98	Cash And Short Term Investments
Net Debt	- 0.98	Cash
Other Stockholder Equity	- 0.98	Retained Earnings